Genscript Biotech (1548.HK) Stock Price
Genscript Biotech Price
Revenue has compounded at 25.0% per year over the past 13 years to 959.53 M USD. Earnings per share have grown at 54.3% per year over the last 12 years. Genscript Biotech's net margin stands at -55.5%, up from -73.2% several years earlier. Genscript Biotech currently offers a dividend yield of about 0.24%. The payout ratio is around 10% of earnings. Analysts set a median price target of 2.53 USD, implying 49.6% below the current price. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus. The stock trades about 271% above its 52-week low.
Genscript Biotech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Genscript Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genscript Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genscript Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Genscript Biotech Price |
|---|---|
| 9/18/2026 | 5.01 USD |
| 9/17/2026 | 4.74 USD |
| 9/16/2026 | 4.15 USD |
| 9/15/2026 | 4.13 USD |
| 9/14/2026 | 4.35 USD |
| 9/11/2026 | 4.13 USD |
| 9/10/2026 | 4.08 USD |
| 9/9/2026 | 4.30 USD |
| 9/8/2026 | 4.42 USD |
| 9/7/2026 | 3.95 USD |
| 9/4/2026 | 4.01 USD |
| 9/3/2026 | 4.63 USD |
| 9/2/2026 | 4.58 USD |
| 9/1/2026 | 4.64 USD |
| 8/31/2026 | 4.29 USD |
| 8/28/2026 | 4.47 USD |
| 8/27/2026 | 4.53 USD |
| 8/26/2026 | 4.48 USD |
| 8/25/2026 | 4.47 USD |
| 8/24/2026 | 4.16 USD |
| 8/21/2026 | 4.39 USD |
| 8/20/2026 | 4.26 USD |
| 8/19/2026 | 3.75 USD |
| 8/18/2026 | 3.61 USD |
| 8/17/2026 | 3.33 USD |
| 8/14/2026 | 3.17 USD |
| 8/13/2026 | 3.31 USD |
| 8/12/2026 | 3.17 USD |
| 8/11/2026 | 3.13 USD |
| 8/10/2026 | 3.08 USD |
Genscript Biotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Genscript Biotech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| SHARESB |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.15 | 0.23 | 0.27 | 0.39 | 0.49 | 0.63 | 0.56 | 0.59 | 0.96 | 0.90 | 1.15 | 1.44 | 1.08 | 1.18 | 1.29 |
| 32.56 | 33.33 | 51.97 | 18.18 | 42.86 | 25.64 | 27.55 | -10.40 | 6.07 | 61.45 | -6.47 | 28.21 | 25.22 | -24.86 | 9.43 | 9.12 |
| 66.67 | 68.42 | 68.40 | 65.93 | 65.38 | 57.55 | 48.64 | 48.21 | 45.79 | 57.66 | 57.66 | 57.66 | 57.66 | 57.66 | 57.66 | 57.66 |
| 76.00 | 104.00 | 158.00 | 180.00 | 255.00 | 282.00 | 304.00 | 270.00 | 272.00 | 553.00 | 517.25 | 663.14 | 830.36 | 623.93 | 682.74 | 745.02 |
| 26.00 | 37.00 | 8.00 | -123.00 | -206.00 | -522.00 | -431.00 | 160.00 | -108.00 | 265.00 | 27.00 | 232.00 | 443.00 | 123.00 | 145.00 | – |
| 22.81 | 24.34 | 3.46 | -45.05 | -52.82 | -106.53 | -68.96 | 28.57 | -18.18 | 27.63 | 3.01 | 20.17 | 30.76 | 11.37 | 12.25 | – |
| 0.03 | 0.03 | 0.02 | -0.10 | -0.20 | -0.36 | -0.23 | -0.10 | 2.96 | -0.53 | 0.01 | 0.17 | 0.31 | – | – | – |
| 52.94 | – | -19.23 | -557.14 | 112.50 | 75.49 | -36.87 | -57.96 | -3,216.84 | -117.97 | -101.50 | 2,000.00 | 82.74 | – | – | – |
| – | 0.01 | – | – | – | – | – | – | – | – | 0.01 | 0.01 | 0.01 | – | – | – |
| 1.71 | 1.73 | 1.84 | 1.86 | 1.90 | 2.04 | 2.10 | 2.11 | 2.12 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Genscript Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genscript Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genscript Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Genscript Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genscript Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Genscript Biotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Genscript Biotech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Genscript Biotech business model & stock analysis
Genscript Biotech SWOT Analysis
Strengths
1. Leading Biotech Company: GenScript Biotech Corp is a renowned biotech company known for its expertise and innovative solutions in the industry.
2. Established Brand: The company has a strong brand presence globally, with a reputation for quality products and services.
3. Diverse Product Portfolio: GenScript offers a wide range of biotech products and services, catering to the needs of customers from various sectors.
Weaknesses
1. Dependency on Research and Development: GenScript's success heavily relies on continuous research and development efforts, making it susceptible to any disruptions in these processes.
2. Vulnerability to Market Fluctuations: As a player in the biotech industry, GenScript is affected by market volatility, regulatory changes, and economic conditions, which may impact its financial stability.
3. Limited Geographic Presence: Although GenScript operates globally, its reach may be limited in certain countries, potentially hindering expansion opportunities.
Opportunities
1. Growing Demand for Biotech Solutions: The global biotech market is experiencing significant growth, providing opportunities for GenScript to capitalize on the increasing demand for its products and services.
2. Mergers and Acquisitions: GenScript can explore strategic partnerships, mergers, or acquisitions to expand its market presence, acquire new technologies, and gain a competitive edge.
3. Emerging Markets: Targeting emerging markets with high growth potential, such as Asia-Pacific and Latin America, can provide GenScript with new customers and revenue streams.
Threats
1. Intense Competition: The biotech industry is highly competitive, with numerous players vying for market share. Increased competition can pose challenges for GenScript in maintaining its market position.
2. Regulatory Risks: Adhering to complex and evolving regulations across different countries poses a potential risk for GenScript, as non-compliance could lead to penalties and reputational damage.
3. Technological Advancements: Rapid technological advancements in the biotech field can impact GenScript's offerings, making it crucial for the company to stay at the forefront of innovation.
Genscript Biotech Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Genscript Biotech historical P/E ratio, EBIT multiple, and P/S ratio
Genscript Biotech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Genscript Biotech's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Genscript Biotech's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Genscript Biotech's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Genscript Biotech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Genscript Biotech Dividend History
1 years of dividend payments
Genscript Biotech dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Genscript Biotech forecasts and price targets in September 2026
Analyst Price Targets 2026Genscript Biotech Earnings Calls
Genscript Biotech Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 3/24/2027 | 0.08USD | - | 3.89 BUSD | - | 2027 Q1 |
| 8/16/2026 | -USD | -0.46USD | 3.01 BUSD | - | 2026 Q2 |
| 3/15/2026 | -0.23USD | -0.23USD | 3.43 BUSD | - | 2025 Q4 |
| 8/16/2025 | 0.63USD | -0.17USD | 4.40 BUSD | - | 2025 Q2 |
| 3/11/2025 | -0.08USD | 11.50USD | 5.02 BUSD | - | 2024 Q4 |
| 8/11/2024 | -0.08USD | -0.65USD | 4.28 BUSD | - | 2024 Q2 |
| 3/10/2024 | -0.39USD | -0.25USD | 3.64 BUSD | - | 2023 Q4 |
| 8/20/2023 | -USD | -0.35USD | 53.40 BUSD | - | 2023 Q2 |
| 3/31/2023 | -USD | -0.34USD | 53.44 BUSD | - | 2023 Q1 |
| 3/20/2022 | -USD | -1.01USD | 466.43 MUSD | - | 2022 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Genscript Biotech stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Genscript Biotech shareholder structure
| % | Name |
|---|---|
2.25789% | |
1.91786% | |
1.38586% | |
0.62676% | |
0.61639% | |
0.29146% |
Genscript Biotech Beneficial Ownership Filings (SEC 13D/G)
Genscript Biotech Executives and Management Board
13 members · avg. age 61 · 23 % women
Ms. Weihui Shao (44)
Chief Executive Officer
3.62 M USD
Management
Ms. Ye Wang (56)
President, Co-Founder, Executive Director · since 2015
Dr. Li Zhu (75)
Executive Director, Chief Strategy Officer · since 2010
Mr. Shiniu Wei (45)
Chief Financial Officer
Ms. Wai Ling Wong
Company Secretary
Board of Directors
Dr. Fangliang Zhang (60)
Executive Director · since 2015
Mr. Jiange Meng (56)
Executive Chairman of the Board · since 2010
Mr. Jiuan Pan (56)
Non-Executive Independent Director
Mr. Yiu Leung Cheung (66)
Non-Executive Independent Director
Mr. Chenyang Shi (57)
Non-Executive Independent Director
Dr. Alphonse Galdes (72)
Non-Executive Independent Director
Genscript Biotech Supply Chain
Genscript Biotech Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.64 | 0.34 | 0.83 | ||
| 2 | -0.77 | -0.49 | 0.58 |
Frequently asked questions about Genscript Biotech
The business model of Genscript Biotech Corp focuses on providing integrated solutions for life sciences research and drug discovery. The company offers a comprehensive range of products and services, including gene synthesis, protein expression, antibody development, and molecular diagnostics. Genscript Biotech Corp aims to accelerate biological research and development by providing high-quality and cost-effective solutions to scientists worldwide. Through its innovative technologies and expertise, the company has gained a strong reputation in the biotech industry. Genscript Biotech Corp continually strives to enhance its capabilities and expand its product portfolio to meet the evolving needs of the scientific community.
Genscript Biotech Corp is primarily active in the biotechnology industry.
The main competitors of Genscript Biotech Corp in the market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Sartorius AG.
Genscript Biotech Corp is a leading biotechnology company with a rich history and background. Established in 2002, the company specializes in providing high-quality services and products in the field of life sciences research. Genscript is dedicated to enabling advancements in scientific discoveries and breakthroughs through its expertise in gene synthesis, custom protein production, antibody development, and many other gene-related services. With its state-of-the-art facilities and a global customer base, Genscript has become a trusted partner for researchers and pharmaceutical companies worldwide. The company's commitment to innovation and excellence has helped propel it to the forefront of the biotech industry, making Genscript Biotech Corp a reliable choice for investors seeking opportunities in this dynamic sector.
Genscript Biotech Corp has achieved several significant milestones. As a leading biotechnology company, Genscript has made remarkable strides in the field. Notably, the company successfully completed the genome synthesis of the E. coli bacterium in 2010, which was a groundbreaking achievement. In 2015, Genscript became the first Chinese biotech firm to be listed on the Hong Kong Stock Exchange, marking a significant milestone for the company. Moreover, Genscript has continuously expanded its portfolio of services and products, catering to various research areas and providing innovative solutions to the scientific community. With such achievements, Genscript Biotech Corp stands as a prominent player in the biotech industry.
Genscript Biotech Corp is primarily present in several countries and regions across the globe. The company has a strong foothold in China, where its headquarters are located. Additionally, Genscript Biotech Corp has a significant presence in the United States, with offices and operations spread across various states. The company has also established a strong international presence, with operations and collaborations in Europe, Asia, and other regions worldwide. With its global reach, Genscript Biotech Corp continues to expand its presence and deliver innovative solutions in the field of biotechnology.
Genscript Biotech Corp represents values of innovation, collaboration, and commitment to scientific advancement. With a strong corporate philosophy centered around providing quality products and services, Genscript strives to enhance the understanding and application of biotechnology worldwide. The company is dedicated to delivering cutting-edge research tools, custom solutions, and high-quality services to enable scientists and researchers in various fields. Genscript Biotech Corp aims to foster a culture of excellence, integrity, and customer-centricity, positioning itself as a global leader in the biotech industry.
Analysts currently set an average price target of 2.67 USD for the Genscript Biotech stock (median: 2.53 USD), implying -46.7 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Genscript Biotech stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genscript Biotech to generate revenue of 897.78 M USD and earnings per share of 0.00 USD.
Converted at the current exchange rate, the Genscript Biotech share trades at 4.37 EUR (5.01 USD).
The Genscript Biotech share (1548.HK) is listed on 4 stock exchanges, including: Hongkong (HKEX) (1548.HK), Frankfurt (G51.F), München (G51.MU).
GenScript Biotech Corp is a leading company in the biotech industry that specializes in the development and manufacture of high-quality biological products and services. The company offers a wide range of products and services, including DNA synthesis, protein production, antibody production, cell line development, and diagnostic tools. The company's divisions include proprietary products, manufacturing, and CRO (Contract Research Organization). Proprietary products contribute a large portion of the company's revenue and include various products such as CRISPR/Cas9 kits, DNA sequencing, protein analysis, and antibody services. GenScript Biotech's manufacturing business model is highly tailored to customer needs. It is based on critical procedures that incorporate proven expertise and patented technologies. The model includes a targeted approach to developing the necessary production processes, quality controls at every step of the manufacturing process, and support throughout the customer's entire lifecycle. An essential goal of the company is to support customers in every phase of the manufacturing process to ensure smooth and successful production. The Contract Research Organization (CRO) division of GenScript Biotech focuses on supporting customers in early stages of biological research or clinical trials. Through partnerships with the company, customers are supported through services such as protein engineering, cell line development, cell therapy, in vivo services, and pharmaceutical development. The company also offers a variety of diagnostic solutions and laboratory services. Examples include the development of cellular assays, reagent manufacturing, and DNA sequencing services. Overall, GenScript Biotech Corp is strongly focused on providing rapid and flexible service to its customers by offering a wide range of biopharmaceuticals, diagnostic tools, and laboratory services. The company has a global presence with offices in China, the USA, Europe, Japan, and Singapore. As a company that prioritizes innovation and quality, GenScript Biotech holds a strong position in the biotechnology market. With its various divisions and high-quality offering of products and services, the company provides its customers with a valuable partner to achieve their goals in biotechnology.
The expected revenue of Genscript Biotech is 897.78 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Genscript Biotech is 8.01 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Genscript Biotech is currently 1,356.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genscript Biotech stock.
The price-to-sales ratio (P/S) of Genscript Biotech is currently 12.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genscript Biotech stock.
The Eulerpool Quality Score for Genscript Biotech is 5/10.
The ISIN of Genscript Biotech is KYG3825B1059. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Genscript Biotech is A2ACSB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Genscript Biotech is 1548.HK. The ticker symbol is used to trade Genscript Biotech shares on the stock exchange.
Over the past 12 months, Genscript Biotech paid a dividend of 0.01 USD . This corresponds to a dividend yield of about 0.24 %. For the coming 12 months, Genscript Biotech is expected to pay a dividend of 0.01 USD.
The current dividend yield of Genscript Biotech is 0.24 %.
Genscript Biotech paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0.01 USD are expected. This corresponds to a dividend yield of 0.24 %.
Genscript Biotech is assigned to the 'Health' sector.
To receive the latest dividend of Genscript Biotech from 6/21/2017 amounting to 0.01 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2017.
The last dividend was paid out on 6/21/2017.
In the year 2017, Genscript Biotech distributed 0.01 USD as dividends.
The dividends of Genscript Biotech are distributed in USD.
Genscript Biotech stock
Genscript Biotech Peer Group
Genscript Biotech Ticker
Genscript Biotech FIGI
All fundamentals and in-depth analysis of Genscript Biotech
Our stock analysis for Genscript Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genscript Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.